

Patient Name

DOB

Cell Phone

Address

KRYSTEXXA (pegloticase)

Status	<input type="checkbox"/> New Therapy <input type="checkbox"/> Order Renewal <input type="checkbox"/> Dosage or Frequency Change			
Diagnosis	<input type="checkbox"/> ICD 10 Code: M1A.____ Chronic gout <input type="checkbox"/> ICD 10 Code: _____ Other: _____			
Pertinent Medical History	Prior (Failed or Intolerant) Gout Therapy (if any): <input type="checkbox"/> Allopurinol <input type="checkbox"/> Febuxostat <input type="checkbox"/> Probenecid <input type="checkbox"/> other: _____ Has patient experienced at least 3 gout flares in previous 18 months? <input type="checkbox"/> Y <input type="checkbox"/> N Has patient stopped taking oral urate-lowering therapy? <input type="checkbox"/> Y <input type="checkbox"/> N Is patient G6PD deficient? <input type="checkbox"/> Y <input type="checkbox"/> N			
Labs	Glucose-6-phosphate dehydrogenase (G6PD) results = _____ Date: _____ Serum Uric Acid level = _____ Date: _____ Labs to be drawn by: <input type="checkbox"/> Infusion Clinic <input type="checkbox"/> Referring Physician If Infusion Clinic: <input type="checkbox"/> Serum Uric Acid level approximately 24-48 hours prior to each infusion. Hold infusion if 2 consecutive levels are above 6mg/dl. If patient misses 2 doses (4 weeks), resuming treatment must be cleared by ordering physician or therapy discontinued. <input type="checkbox"/> Other: _____			
Premeds	<input checked="" type="checkbox"/> acetaminophen (Tylenol) 1000mg PO <input checked="" type="checkbox"/> diphenhydramine (Benadryl) 25mg IV <input checked="" type="checkbox"/> methylprednisolone (Solu-Medrol) 100mg IV <input type="checkbox"/> other: _____			
IV Fluids	<input type="checkbox"/> NS TKO <input type="checkbox"/> Other: _____			
Medication Order	<input type="checkbox"/> Krystexxa 8mg/250ml IV every 2 weeks Refills: <input type="checkbox"/> x 6 months <input type="checkbox"/> x _____ doses <input type="checkbox"/> No refills; give this dose only.			
Monitoring	Monitor for signs/symptoms of hypersensitivity during infusion and 60 mins post-infusion. For any signs of infusion reaction: STOP infusion. Contact on-site provider for instruction.			
Additional Orders				
Physician Information	Physician Name	_____	NPI	_____
	Office Contact	_____	Phone	_____
	Provider Signature:	_____	Date	_____



Patient Name
DOB
Cell Phone
Address

KRYSTEXXA (pegloticase)

REQUIRED DOCUMENTATION	
○ Patient Demographics & Insurance Information:	- Copy of patient's insurance card – front and back
○ Clinical / Progress Notes, supporting primary diagnosis:	- 2 most recent office notes - Medication history
○ Most Recent Labs:	- CMP and CBC - Uric acid, Sed rate, G6PD results

FAX to (480) 400-6121
Intake Specialist (480) 927-3800
referral@infuseablecare.com